The number of ordinary shares in issue are 169,117,640.
Shareholders holding more than 3% of the share capital of the Company were:
|Shareholder||Number of shares held||% issued share capital|
|Legal & General Investment Management||24,742,135||14.63%|
|Schroder Investment Management||14,630,383||8.65%|
|Cavendish Asset Management||6,836,445||4.04%|
|Henderson Global Investors||6,602,092||3.90%|
|Milton Asset Management||5,551,297||3.28%|
|Brian George Kennedy||5,398,134||3.19%|
Where applicable, shares held are direct and indirect holdings.
* Christopher Mills, who is a non-executive Director of Quantum Pharma Plc, is the Chief Executive of North Atlantic Smaller Companies Investment Trust plc and also Chief Investment Officer of Harwood Capital LLP.
|Dr. John Brown||73,529||0.04|
In terms of AIM Rules published July 2016 and insofar as it is aware, as at 20 February 2017, 29.7% of the Company's AIM securities was not in public hands.
There are no restrictions on the transfer of securities.
Quantum Pharma Plc is subject to the UK City Code on Takeovers and Mergers.
Other than AIM, the Company's shares are not admitted to or traded on any other exchanges or trading platforms.
Page last updated: 20 February 2017
01 February 2017